Mylan and Theravance Biopharma have won approval for their inhalable treatment, Yupelri.
Designed as a maintenance treatment for patients with chronic obstructive pulmonary disease, Yupelri is the first-ever once-daily, nebulized bronchodilator approved by the FDA for COPD.
Around 16 million Americans have COPD, and the companies say that 9-10 percent of patients prefer a nebulized product to treat the condition.
The companies plan to launch Yupelri in the U.S. later this year.
Read the full Reuters report.